Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer
Listen now
Description
Dr Perez talks to ecancertv at ASCO 2014 about the findings from a large phase III study, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) which suggest that post-surgery (adjuvant) treatment using a combination of two HER2-targeted drugs – trastuzumab and lapatinib – is no more effective than standard treatment with trastuzumab alone for women with early HER2-positive breast cancer.
More Episodes
At ASCO 2014, Dr O'Day provides ecancertv with his expert opinion on the findings from a large phase I study of 411 patients with advanced melanoma which showed that the PD-1 targeting antibody MK-3475 yields long-term responses in a high percentage of patients.
Published 07/15/14
Published 07/15/14
ecancer's Prof McVie provides a roundup of the main points of discussion from ASCO 2014.
Published 07/11/14